Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A cellular therapy for ocular degeneration

A cell and stem cell technology, applied in the field of cell-based therapy or regenerative therapy, which can solve the problem of low expansion ability of adult stem cells

Inactive Publication Date: 2009-07-15
CENTOCOR
View PDF30 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] In addition, adult stem cells have a lower ability to expand in culture than embryonic stem cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A cellular therapy for ocular degeneration
  • A cellular therapy for ocular degeneration
  • A cellular therapy for ocular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0097] Use of mesenchymal stem cells in the treatment of retinitis pigmentosa

[0098] Genetically engineered Royal College of Surgeon (RCS) rats are predisposed to experience significant visual loss caused by fundamental dysfunction of retinal pigment epithelial (RPE) cells. Using this model, the efficacy of subretinal transplantation of mesenchymal stem cell populations to protect photoreceptors was determined in RCS rats. In this degenerative model, rod function is lost within 30-60 days of life. Cone function is usually lost within 3 months.

[0099] Preparation of MSCs for transplantation

[0100] Adult MSC cultures (cat# PT-2501, Cambrex) were expanded in vitro for a total of 6 passages. All cells at 5,000 cells / cm 2 First inoculated in uncoated T75 flasks containing mesenchymal stem cell growth medium supplemented according to the manufacturer's (Cambrex) instructions. For subsequent passages, all cells were processed as follows. After trypsin hydrolysis, viable c...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Compositions and methods applicable to cell-based or regenerative therapy for ophthalmic diseases and disorders comprising mesenchymal stem cells, particularly those characterized by the expression of at least one of the following surface markers: CD29, CD44, CD105 or CD166, and the lack of expression of at least one of CD14, CD34 or CD45.

Description

field of invention [0001] The present invention relates to the field of cell-based therapy or regenerative therapy for ophthalmic diseases and disorders. Specifically, the present invention provides mesenchymal stem cells and methods, optionally pharmaceutical compositions, devices for regenerating or repairing eye cells and tissues. Background of the invention [0002] As a complex and sensitive human organ, the eye is subject to various diseases and other harmful conditions that affect its ability to function normally. Many of these conditions are associated with damage or degeneration of specific eye cells and the tissues that these cells make up. For example, optic nerve and retinal diseases and degenerative disorders are the leading causes of blindness worldwide. Damage and degeneration of the cornea, lens, and related eye tissues is another important cause of vision loss. The retina contains seven layers of interacting cells that convert light signals into nerve sig...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12N5/06C12N5/08C12N5/16A61K48/00A01N63/00A01N65/00A61K35/12C12N5/0775
CPCA61K2035/124C12N5/0668C12N5/0663C12N5/0605A61P27/02A61P27/06A61P27/12A61P9/10A61K9/0048A61K35/28A61K45/06
Inventor S·米斯特里
Owner CENTOCOR
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com